Sex: U
Vaccine: COVID19
Symptoms: Vaccination site swelling, Vomiting
Clinical narrative: Severe malaise/feeling sick present with significant interference with activity; Significant injection site pain preventing daily activity/ Significant injection site tenderness (tenderness during rest); Mild injection site redness; Mild injection site swelling; Mild fever (100.4 to 101.2 °F); Severe fatigue with significant interference with activity; Severe muscle pain significantly interfering with activity; Joint pain with significant interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache that prevented daily activity OR required any use of a prescription pain reliver; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Severe malaise/feeling sick present with significant interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling) and PYREXIA (Mild fever (100.4 to 101.2 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Severe malaise/feeling sick present with significant interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain with significant interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that prevented daily activity OR required any use of a prescription pain reliver). At the time of the report, MALAISE (Severe malaise/feeling sick present with significant interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/ Significant injection site tenderness (tenderness during rest)), VACCINATION SITE ERYTHEMA (Mild injection site redness), VACCINATION SITE SWELLING (Mild injection site swelling), PYREXIA (Mild fever (100.4 to 101.2 °F)), FATIGUE (Severe fatigue with significant interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain with significant interference with activity), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that prevented daily activity OR required any use of a prescription pain reliver) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 Degree F).         No concomitant medications were reported.  It was reported that patient had significant injection site pain preventing daily activity, significant injection site tenderness (tenderness during rest), mild injection site redness, mild injection site swelling, mild fever (100.4 to 101.2 Degree F), severe fatigue with significant interference with activity, severe malaise/feeling sick present with significant interference with activity, severe muscle pain significantly interfering with activity, joint pain with significant interference with activity, Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting, headache that prevented daily activity or required any use of a prescription pain reliver anytime during the 2 days after the COVID-19 vaccination, which occurred on Tuesday, 19-Dec-2023 and Wednesday, 20-Dec-2023.  Treatment medication included pain reliver.  The Subject ID was reported.   The Subject ID was reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756041 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756041:Same reporter